Dianthus Therapeutics (DNTH) files $600M mixed shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
This biotech stock is a Top Pick for 2026 at Oppenheimer
January 30, 2026 2:00 PM ESTOne biotech company is drawing attention from analysts at Jefferies, which highlighted its pipeline momentum and raised its price target to $125 from $62, calling the stock a top pick ahead of 2026 catalysts, in a note to clients this week.
Jefferies noted that Dianthus Therapeutics (NASDAQ: DNTH) shares have already climbed 22 percent this year, outpacing the XBIs 5 percent gain,... More
